BioAtla Investor Presentation Deck

CAB-CTLA4 Selectively Active in Tumor Microenvironment, thereby Reducing Immune Related Adverse Events (irAEs) Non-CAB CTLA-4 bicatla inhibitors anti-CTLA4 Severe irAEs anti-CTLA4 Normal Cell Normal Cell (alkaline) Cancer cell (acidic) ↑ Cytotoxic (CD8+) T cells ⇓T regulatory cells Minimized irAEs CAB-anti-CTLA4 Normal Cell CAB CTLA-4 Tumor selective binding CAB-anti-CTLA4 BioAtla| Overview 10

View entire presentation